Sigma-Aldrich
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sigma-Aldrich - overview
Location
St. Louis, MO, US
Primary Industry
Biotechnology
About
Sigma-Aldrich, a subsidiary of Merck KGaA, specializes in providing a vast array of life science products and services, supporting research, biotechnology, and pharmaceutical drug development. Sigma-Aldrich, based in St. Louis, US, is engaged in the production and distribution of a wide range of chemicals and laboratory products. The company operates under the parent company Merck KGaA and has a history of providing essential services to researchers and industry professionals.
It was founded with a vision to support scientific exploration and has established a global footprint in markets including North America, Europe, and Asia-Pacific. Bernd Krueger and Gabriela Moderegger currently serve as co-CEOs, driving the company’s vision and operational effectiveness. MilliporeSigma specializes in an extensive range of life science products and service solutions that support research, biotechnology development, and pharmaceutical drug production. Their core offerings include analytical chemistry products, cell culture and analysis tools, and lab water solutions, which are designed to aid scientists and researchers in various sectors, including pharmaceuticals, biotech, and academia.
The company's products are utilized in applications such as drug discovery, development, and production, focusing on enhancing laboratory efficiency and accuracy. MilliporeSigma serves a diverse customer base across multiple geographical markets, ensuring that their innovative solutions cater to the specific needs of researchers and biomanufacturers worldwide. MilliporeSigma generates revenue through a variety of structured transactions predominantly in the B2B space, where they engage with clients such as research institutions, pharmaceutical companies, and biotech firms. Their business model includes direct sales of individual products, subscription services for ongoing supply needs, and partnerships for custom solutions tailored to specific research requirements.
Flagship offerings, such as the Sigma-Aldrich® and Millipore® brands, contribute significantly to their revenue streams through established pricing plans that reflect the advanced technology and quality assurance associated with their products. The company emphasizes long-term relationships with its clients, facilitating bulk orders and providing consultative services that optimize workflows in life science research and production environments. MilliporeSigma is focused on developing new products designed to enhance laboratory workflows, with several launches planned for the upcoming year. The company aims to expand its reach into emerging markets across Asia and South America by the end of 2025 to cater to the growing demand in these regions.
Recent funding will be allocated to support the development of innovative product lines and to strengthen their market presence through strategic partnerships in key geographical areas.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.sigmaaldrich.com
Total Amount Raised
Subscriber access only
Sigma-Aldrich - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | BioReliance Corporation | - | ||||||||
| Trade Sale | Completed | Cerilliant Corporation | - |
Displaying 1 - 2 of 2

Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.